ANEB — Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 2
• Website: https://www.anebulo.com

Latest SEC filings for ANEB

• 10-Q — 2026-02-12
• 8-K — 2026-02-12
• 8-K — 2026-02-06
• 8-K — 2026-01-29
• 8-K — 2026-01-27
• 8-K — 2025-12-22

Abrir análisis completo

Educational tool only — not investment advice.